ES2312347T3 - Vacunas atenuadas quimericas humano-bovino del virus parainfluenza (piv). - Google Patents

Vacunas atenuadas quimericas humano-bovino del virus parainfluenza (piv). Download PDF

Info

Publication number
ES2312347T3
ES2312347T3 ES00941614T ES00941614T ES2312347T3 ES 2312347 T3 ES2312347 T3 ES 2312347T3 ES 00941614 T ES00941614 T ES 00941614T ES 00941614 T ES00941614 T ES 00941614T ES 2312347 T3 ES2312347 T3 ES 2312347T3
Authority
ES
Spain
Prior art keywords
piv
chimeric
virus
antigenome
genome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00941614T
Other languages
English (en)
Spanish (es)
Inventor
Alexander C. Schmidt
Mario H. Skiadopoulos
Peter L. Collins
Brian R. Murphy
Jane E. Bailly
Anna P. Durbin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Application granted granted Critical
Publication of ES2312347T3 publication Critical patent/ES2312347T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
ES00941614T 1999-07-09 2000-06-16 Vacunas atenuadas quimericas humano-bovino del virus parainfluenza (piv). Expired - Lifetime ES2312347T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14313499P 1999-07-09 1999-07-09
US143134P 1999-07-09

Publications (1)

Publication Number Publication Date
ES2312347T3 true ES2312347T3 (es) 2009-03-01

Family

ID=22502741

Family Applications (1)

Application Number Title Priority Date Filing Date
ES00941614T Expired - Lifetime ES2312347T3 (es) 1999-07-09 2000-06-16 Vacunas atenuadas quimericas humano-bovino del virus parainfluenza (piv).

Country Status (12)

Country Link
EP (3) EP2019141A3 (enExample)
JP (1) JP4813711B2 (enExample)
KR (1) KR100940776B1 (enExample)
CN (2) CN101392239A (enExample)
AT (1) ATE408693T1 (enExample)
BR (1) BR0013190A (enExample)
CA (1) CA2378661A1 (enExample)
DE (1) DE60040289D1 (enExample)
ES (1) ES2312347T3 (enExample)
IL (2) IL147167A0 (enExample)
MX (1) MXPA01013302A (enExample)
WO (1) WO2001004320A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192593B2 (en) 1997-05-23 2007-03-20 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of recombinant parainfluenza viruses (PIVs) as vectors to protect against infection and disease caused by PIV and other human pathogens
MXPA01008108A (es) * 1999-12-10 2004-11-12 Health Uso de virus de parainfluenza recombinante (pivs) como vectores para la proteccioncontra la infeccion y enfermedad provocadas por piv y otros patogenos humanos.
US6764685B1 (en) 2000-03-21 2004-07-20 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines
AU2001271909A1 (en) * 2000-07-05 2002-01-14 The Government Of The United States Of America, As Represented By The Department Of Health And Human Services Attenuated human-bovine chimeric parainfluenza virus (piv) vaccines
UA93981C2 (ru) 2001-01-19 2011-03-25 Вироновативе Б.B. Вирус, который вызывает заболевание дыхательных путей у чувствительных k этому млекопитающих
US8715922B2 (en) 2001-01-19 2014-05-06 ViroNovative Virus causing respiratory tract illness in susceptible mammals
EP1456398B1 (en) 2001-11-21 2011-05-11 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Recovery of recombinant human parainfluenza virus type 1 (hpivi) from cdna
CA2477235A1 (en) 2002-02-21 2003-09-04 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
US7820181B2 (en) 2002-09-18 2010-10-26 The United States Of America As Represented By The Department Of Health And Human Services Recovery of recombinant human parainfluenza virus type 2 (HPIV2) from cDNA and use of recombinant HPIV2 in immunogenic compositions and as vectors to elicit immune responses against PIV and other human pathogens
JP2007524372A (ja) 2003-02-28 2007-08-30 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ 組換えヒトメタニューモウイルスおよびその使用
CA2523657A1 (en) * 2003-04-25 2005-03-31 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
JP2007525178A (ja) 2003-04-25 2007-09-06 メッドイミューン バクシーンズ，インコーポレイティド メタニューモウイルス株、そのワクチン製剤における用途、抗原性配列の発現のためのベクターとしての用途、並びにウイルス増殖方法
KR100999316B1 (ko) 2003-06-09 2010-12-10 와이어쓰 엘엘씨 ｃＤＮＡ로부터의 비분절 네가티브 쇄 ＲＮＡ 바이러스의회수를 위한 개선된 방법
CN107818197B (zh) * 2017-09-15 2021-05-25 南京航空航天大学 一种基于piv技术的超声速翼型的测力方法和装置
GB201816873D0 (en) * 2018-10-17 2018-11-28 Imperial Innovations Ltd Fusion protein
CN113322241B (zh) * 2021-05-14 2023-06-13 金宇保灵生物药品有限公司 一种牛副流感病毒3型病毒株bpiv3-nm及其应用
CN116676275B (zh) * 2023-03-17 2024-06-07 北京赛尔富森生物科技有限公司 A基因型嵌合腮腺炎病毒株和制备方法及用途
TW202535439A (zh) 2023-11-17 2025-09-16 美商賽諾菲巴斯德公司 海藻糖疫苗調配物
CN118909958B (zh) * 2024-07-25 2025-02-07 中国兽医药品监察所 一株牛副流感病毒3型np蛋白杂交瘤细胞株及单抗和在检测抗原中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GB9200117D0 (en) * 1992-01-06 1992-02-26 Connaught Lab Production of recombinant chimeric proteins for vaccine use
ATE181112T1 (de) 1995-08-09 1999-06-15 Schweiz Serum & Impfinst Dem genom von minussträngigen rna-viren entsprechende cdna und verfahren zur herstellung von infektiösen minussträngigen rna-viren
JPH11513372A (ja) * 1995-09-22 1999-11-16 コノート ラボラトリーズ リミテッド パラインフルエンザウイルスの糖タンパクおよびワクチン
US5869036A (en) * 1995-12-08 1999-02-09 St. Louis University Live attenuated vaccines based on CP45 HPIV-3 strain and method to ensure attenuation in such vaccine
EP2112220A3 (en) 1996-07-15 2010-01-06 The Government of the United States of America, as represented by The Department of Health and Human Services Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences
BR9809456B1 (pt) * 1997-05-23 2011-06-28 molécula isolada de polinucleotìdeo, composição de célula ou isenta de célula, partìcula de piv infeciosa, atenuada e imunogênica, e, composição imunogênica.

Also Published As

Publication number Publication date
EP2019141A2 (en) 2009-01-28
EP1194564B1 (en) 2008-09-17
BR0013190A (pt) 2002-07-16
EP1194564A1 (en) 2002-04-10
EP2019141A3 (en) 2009-02-04
KR20020022768A (ko) 2002-03-27
CA2378661A1 (en) 2001-01-18
DE60040289D1 (de) 2008-10-30
CN100402651C (zh) 2008-07-16
MXPA01013302A (es) 2004-03-10
EP2019140A2 (en) 2009-01-28
JP2003504064A (ja) 2003-02-04
ATE408693T1 (de) 2008-10-15
EP2019140A3 (en) 2009-02-04
WO2001004320A1 (en) 2001-01-18
JP4813711B2 (ja) 2011-11-09
IL147167A (en) 2010-06-16
IL147167A0 (en) 2002-08-14
KR100940776B1 (ko) 2010-02-11
CN101392239A (zh) 2009-03-25
CN1369011A (zh) 2002-09-11

Similar Documents

Publication Publication Date Title
ES2312347T3 (es) Vacunas atenuadas quimericas humano-bovino del virus parainfluenza (piv).
JP4795597B2 (ja) パラインフルエンザウィルス（ｐｉｖ）及びヒトの病原体により引き起こされる感染及び疾病を保護するためへの組換えｐｉｖのベクターとしての使用
ES2283306T3 (es) Vacunas de virus parainluenza recombinante atenuadas por supresion o eliminacion de un gen no esencial.
US20120064569A9 (en) Production of attenuated negative stranded rna virus vaccines from cloned nucleotide sequences
AU2009202359A1 (en) Recovery of recombinant human parainfluenza virus type 1 (HPIV1) from cDNA use of recombinant HPIV1 in immunogenic compositions and as vectors to elicit immune responses against PIV and other human pathogens
US7622123B2 (en) Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines
US7201907B1 (en) Attenuated human-bovine chimeric parainfluenza virus(PIV) vaccines
US7632508B2 (en) Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines
US7314631B1 (en) Use of recombinant live-attenuated parainfluenza virus (PIV) as a vector to protect against disease caused by PIV and respiratory syncytial virus (RSV)
US20110189232A1 (en) RECOMBINANT HUMAN PARAINFLUENZA TYPE 1 VIRUSES (HPIV1s) CONTAINING MUTATIONS IN OR DELETION OF THE C PROTEIN ARE ATTENUATED IN AFRICAN GREEN MONKEYS AND IN CILIATED HUMAN AIRWAY EPITHELIAL CELLS AND ARE POTENTIAL VACCINE CANDIDATES FOR HPIV1
WO2002002605A2 (en) Attenuated human-bovine chimeric parainfluenza virus (piv) vaccines
AU783189B2 (en) Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines